B2M and neoplasm: The majority (7/9) of the control mice had detectable PSA at 3 weeks after intra-tibial injection, whereas the anti-β2-M Ab treated group had delayed tumor formation and less detectable PSA levels (3/9 at 3 weeks after tumor injection).